


**Online Supplementary Figure S1. OPTIMA Study Schematic And Post Hoc Analysis**

**Populations.** ADA=adalimumab; DAS28(CRP)=28-joint modified Disease Activity Score based on C-reactive protein; LDA=low disease activity; MTX=methotrexate; PBO=placebo. \*MTX titrated to 20 mg/wk by week 8. †Patients entering period 2. ‡LDA based on DAS28(CRP) <3.2 at weeks 22 and 26. §This analysis group included data from the ADA-continuation arm, adjusted with a scaling factor that was based on the total number of patients in the ADA-continuation and ADA-withdrawal arms, so that both arms made equal contributions to the merged data.



**Online Supplementary Figure S2. Percentage of Patients With Concomitant Glucocorticoids Use Who Achieved Outcomes Stratified by Initial Treatment Regimen. (A)**

LDA based on DAS28(CRP) <3.2 at weeks 26, 52, and 78. (B) Normal function based on HAQ-DI <0.5 at weeks 26, 52, and 78. ADA=adalimumab; CRP=C-reactive protein; DAS28=28-joint modified Disease Activity Score; HAQ-DI=Disability Index of the Health Assessment Questionnaire; LDA=low disease activity; MTX=methotrexate; PBO=placebo. \**P*<0.001, chi-square test. Missing DAS28(CRP) and HAQ-DI data were imputed using last observation carried forward.

